Navigation Links
BioMolecular Therapeutics, a New Global Player in RNAi Therapeutics, Launches Company and Adds Key Advisors

SEOUL, South Korea, Oct. 19 /PRNewswire/ -- BioMolecular Therapeutics, Inc. (BMT, Inc.), a new Seoul-based RNAi therapeutics company with a proprietary technology designed to reduce significantly deleterious side effects triggered by conventional siRNA, announced that it has launched its global operations. The company is currently developing a novel RNAi therapeutic for age-related macular degeneration (AMD), based on its asymmetric shorter-duplex siRNA (asiRNA) technology, originally published in Molecular Therapy in 2009 as a featured article. Early studies suggest that the asiRNA technology will allow the application of RNAi therapeutics in fields where innate immune stimulation needs to be avoided, such as AMD. The goal of an RNAi therapeutic is to target specifically only the gene or genes implicated in the disease. In AMD, activation of the innate immune response could elicit off-target effects, potentially hastening the progression of the disease. Two previous clinical trials using traditional siRNA as an AMD therapeutic were terminated at Phase II and III because of unintended activation of the patients' immune response.

BMT's leadership team includes Dong-ki Lee, Ph.D., the inventor of the company's proprietary technology, and Sun woo Hong, Ph.D., BMT's founding CEO. Dr. Dong-ki Lee is associate professor of chemistry at Sungkyunkwan University in Suwon, Korea, and the recipient of the prestigious Global Research Laboratory grant from the Korean government for the development of novel RNAi therapeutics. Dr. Sun Woo Hong has strong expertise in siRNA and genomics research, and was research professor at Dongguk University in Seoul, Korea. The company has also named two key advisors, Jayakrishna Ambati, M.D., ophthalmologist and professor at University of Kentucky Medical School, and Johannes Fruehauf, M.D., Ph.D., an experienced biotechnology executive and a specialist in RNAi therapeutics.  

Dr. Ambati will serve as head of BMT's scientific advisory board. He is an authority in ophthalmology and well-known for his seminal contributions in macular degeneration research. His lab made numerous foundational discoveries published in Nature, Nature Medicine, PNAS, and the Journal of Clinical Investigation; these include exceptional findings about the role of the innate immune system in the mechanisms and treatment of AMD. Dr. Ambati won the 2010 Cogan Award from The Association for Research in Vision and Ophthalmology (ARVO) for his contributions in macular degeneration research. "We are extremely honored that Dr. Ambati has agreed to join BMT as chair of our scientific advisory board," said BMT CEO, Sun Woo Hong. "He brings unparalleled expertise and experience in eye disease research, an area so fundamental to our success. We expect that the addition of his expertise will accelerate and strengthen our progress to develop RNAi therapeutics for AMD using our proprietary asiRNA platform."

Dr. Fruehauf has been appointed as the first external director to BMT's board. He is currently vice president of R&D at Aura Biosciences, and founder and president of ViThera Laboratories. Previously, he was a cofounder and VP of research at Cequent Pharmaceuticals, now Marina Biotech, where he oversaw the development from bench into clinical trials of the first oral RNAi therapeutic, CEQ508. Dr. Dong-ki Lee commented, "With Dr. Fruehauf joining our board, we are entering the next phase of BMT's growth. His expertise in building and managing early-stage biotech startup companies and achieving scientific progress towards key milestones is invaluable for our next steps: establishing business relationships and scientific alliances in the United States, and internationally."

The company is making its inaugural U.S. poster presentation at the 6th Annual Meeting of the Oligonucleotide Therapeutics Society, which begins tomorrow in Dana Point, California. The title is Reduced Innate Immune Stimulation by asiRNA Structure: Expanding Therapeutic Application of siRNA.

About Age-Related Macular Degeneration (AMD)

A leading cause of vision loss and blindness, AMD is a disease associated with aging that gradually destroys sharp, central vision. According to the National Eye Institute, age-related macular degeneration affects more than 1.75 million individuals in the United States alone. This number is expected to increase to almost three million by 2020.

About BioMolecular Therapeutics, Inc. (

An early-stage biopharmaceutical company, BMT is pioneering the development of novel RNAi therapeutics to prevent and treat age-related macular degeneration based on the company's proprietary technology, asymmetric shorter-duplex siRNA (asiRNA). This novel RNAi technology significantly reduces deleterious side effects triggered by conventional siRNA, especially, the stimulation of the innate immune system, which makes it feasible to use asiRNA for the treatment of age-related macular degeneration, a disease to which RNAi therapeutics could not be developed using conventional siRNAs. Other potential applications for BMT's technology include therapeutics targeting infectious disease, such as herpes simplex virus (HSV), and cancer. A privately held company based in Suwon, South Korea, BMT was established in 2010.

SOURCE BioMolecular Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
(Date:6/23/2016)... VIEW, Calif. , June 23, 2016 ... a.m. CST on Thursday, July 7, 2016 , , , ... ) , , , , EXPERT PANELISTS:  , ... Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa ... The global pharmaceutical industry is witnessing an ...
(Date:6/23/2016)... PRINCETON, N.J. , June 23, 2016  Guerbet ... of Premier Inc.,s Supplier Horizon Award . ... this year, Guerbet was recognized for its support of ... value creation through clinical excellence, and commitment to lower ... delighted to receive this recognition of our outstanding customer ...
(Date:6/23/2016)... 2016 The Biotechnology industry might ... present great opportunities to investors. assesses the recent ... (NYSE: XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... receive your complimentary trade alerts at: ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
(Date:6/24/2016)... Las Vegas, Nevada (PRWEB) , ... June 24, ... ... their Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and ... The Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement of ... President of North American Capital Sales at HTG Molecular . , ... the commercialization of the HTG EdgeSeq system and associated reagents in North America. , ...
Breaking Medicine News(10 mins):